Article Sidebar

PDF
Date Published: 24/07/2025
Abstract Views: 547
Views PDF: 358
DOI: https://doi.org/10.51298/vmj.v552i2.14943
Issue
Vol. 552 No. 2 (2025)
Section
Các bài báo
How to Cite
Đinh, T. L. A., & Lê , T. Y. (2025). EVALUATING THE RESULTS OF ADJUVANT CHEMOTHERAPY WITH VINORELBINE PLUS CISPLATIN IN PATIENTS WITH STAGE IB - IIIA NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 552(2). https://doi.org/10.51298/vmj.v552i2.14943

EVALUATING THE RESULTS OF ADJUVANT CHEMOTHERAPY WITH VINORELBINE PLUS CISPLATIN IN PATIENTS WITH STAGE IB - IIIA NON-SMALL CELL LUNG CANCER

Thị Lan Anh Đinh, Thị Yến Lê

Main Article Content

Abstract

Objectives: To evaluate the survival and some adverse effects of the adjuvant chemotherapy regimen vinorelbine - cisplatin in patients with stage IIA - IIIA non-squamous non-small cell lung cancer (NSCLC). Patients and method: A retrospective and prospective descriptive study was conducted on 76 patients with stage IB - IIIA non-squamous NSCLC who received adjuvant treatment with the vinorelbine - cisplatin regimen after radical surgery at K Hospital from January 2022 to December 2024. Results: The 3-year disease-free survival (DFS) rate was 76.8%. The 3-year overall survival (OS) rate was 96.1%. The treatment completion rate was 96.1%. The most common hematologic toxicities were neutropenia (69.7%), leukopenia (86.8%), and thrombocytopenia (52.7%), predominantly grade 1 and 2. The most frequent non-hematologic toxicities were fatigue (50%) and nausea/vomiting (59.2%), observed only at grades 1 and 2. High-grade toxicities were rarely reported. Conclusion: Adjuvant treatment with vinorelbine - cisplatin in non-small cell lung cancer is effective in improving survival time. The regimen is well-tolerated with low toxicity and good treatment compliance.

Article Details

Keywords

Non-small cell lung cancer, adjuvant chemotherapy.

References

1. Timothy Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597
2. Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer. 2006;52:207–212
3. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–3559.
4. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004; 22:3852–3859.
5. Kreuter M., Vansteenkiste J., Fischer J.R., et al. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016; 11(1), 85–93.
6. Trần Đình Anh, Trần Văn Thuấn, Đỗ Hùng Kiên. Đánh giá kết quả điều trị hóa chất bổ trợ phác đồ Vinorelbin - Cisplatin trong ung thư phổi không tế bào nhỏ giai đoạn IB-IIIA. Tạp chí y học Việt Nam. 2019; 481: 115-119
7. Charles A Butts, el al. Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. https://doi.org/10.1200/JCO. 2009.24.0333
8. Jean-Yves Douillard, el al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. https://doi.org/ 10.1016/s1470-2045(06)70804